Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial
Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng · 2026
Read Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial by Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13150957.txt.
Description
Qiumin Luo and a large team trial tenofovir alafenamide in chronic hepatitis B during the high-replicative, low-inflammatory phase, when the virus runs high yet the liver stays calm. Antiviral treatment in that phase has not been widely recommended. Their 2026 randomized trial splits 59 such patients: 30 on the drug for 48 weeks and 29 under observation. All were positive for the e-antigen, with normal liver enzymes and high viral counts at the start.
No serious adverse events occurred; one observation patient flared and started treatment. At week 48 the drug group cut its surface antigen and viral count far more than the observation group. A fifth reached viral counts below the low threshold, and one in 30 cleared the e-antigen. Cell analyses hinted that killer-cell types drove the responses. Full suppression stays rare, the team notes.
Catalog record
| CREATOR | Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |